Yet how will our system contemplate funding high-cost therapies that deliver potentially curative benefits over such a wide range of years - from 5 to 75 years. …
New CAR-T data once again highlights the evaluation challenge
June 5, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
The cost of immunoglobulin is on the rise
June 27, 2019 - - Latest News -
NZ's myeloma patients rely on hope - and everything else besides PHARMAC
June 27, 2019 - - Latest News -
Does PHARMAC serve patients or its ideological self?
June 27, 2019 - - Latest News -
NICE's Dillon: Change required to manage the coming 'revolution in medicines'
June 27, 2019 - - Latest News -
MA: More required to attract emerging therapies
June 26, 2019 - - Latest News -
Recognition for Sanofi's employee well-being program
June 26, 2019 - - Latest News -
NZ: Poor access and poor outcomes
June 26, 2019 - - Latest News